Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib

Oncology Reports

Volumn 33, Issue 2, 2015, Pages 526-532

  Wang, Xinzhao ^a   Song, Hongkuan ^b   Yu, Qian ^c   Liu, Qi ^a   Wang, Leilei ^d   Liu, Zhaoyun ^a   Yu, Zhiyong ^d  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b Juxian Hospital of Traditional Chinese Medicine   (China)

^c EMORY UNIVERSITY   (United States)

^d SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

EGFR; MDA MB 468 cells; p53; PI3K Akt; Targeted therapy; Triple negative breast cancer

Indexed keywords

CASPASE 3; CASPASE 9; GEFITINIB; GENDICINE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; ANTINEOPLASTIC AGENT; PROTEIN P53; QUINAZOLINE DERIVATIVE; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMOSENSITIVITY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MDA MB 468 CELL LINE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; ADENOVIRIDAE; ANIMAL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; MICE; PHOSPHATIDYLINOSITOL 3-KINASE; QUINAZOLINES; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919421189     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3665     Document Type: Article

References (39)

1. Podo F, Buydens LM, Degani H, et al: Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 4: 209-229, 2010.
2. Herold CI and Anders CK: New targets for triple-negative breast cancer. Oncology 27: 846-854, 2013.
3. Alvarez RH, Valero V and Hortobagyi GN: Emerging targeted therapies for breast cancer. J Clin Oncol 28: 3366-3379, 2010.
4. Viale G, Rotmensz N, Maisonneuve P, et al: Invasive ductal carcinoma of the breast with the 'triple-negative' phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 116: 317-328, 2009.
5. Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434, 2007.
6. Herbst RS, Giaccone G, Schiller JH, et al: Geftinibin combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22: 785-794, 2004.
7. Von Minckwitz G, Jonat W, Fasching P, et al: A multicentre phase II study on geftinib in taxane-and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 89: 165-172, 2005.
8. Baselga J and Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445-2459, 2005.
9. Baselga J, Albanell J, Ruiz A, et al: Phase II and tumor phar-macodynamic study of geftinib in patients with advanced breast cancer. J Clin Oncol 23: 5323-5333, 2005.
10. Janmaat ML and Giaccone G: Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 8: 576-586, 2003.
11. Normanno N, De Luca A, Maiello MR, et al: The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGfR tyrosine kinase inhibitor geftinib. J Cell Physiol 207: 420-427, 2006.
12. Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R and Colomer R: An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa™)-induced changes in the expression and nucleo-cytoplasmic traffcking of HER-ligands (Review). Int J Mol Med 20: 3-10, 2007.
13. Vousden KH and Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604, 2002.
14. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629, 2007.
15. Brosh R and Rotter V: When mutants gain new powers: news from the mutant p53 feld. Nat Rev Cancer 9: 701-713, 2009.
16. Grob TJ, Heilenkötter U, Geist S, et al: Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer. Breast Cancer Res Treat 134: 561-567, 2012.
17. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70, 2012.
18. Ding L, Ellis MJ, Li S, et al: Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464: 999-1005, 2010.
19. Huang S, Benavente S, Armstrong EA, Li C, Wheeler DL and Harari PM: p53 modulates acquired resistance to EGfR inhibitors and radiation. Cancer Res 71: 7071-7079, 2011.
20. Brand K, Klocke R, Possling A, Paul D and Strauss M: Induction of apoptosis and G2/M arrest by infection with replication-defcient adenovirus at high multiplicity of infection. Gene Ther 6: 1054-1063, 1999.
21. Vogelstein B, Lane D and Levine AJ: Surfng the p53 network. Nature 408: 307-310, 2000.
22. Guida E, Bisso A, Fenollar-Ferrer C, et al: Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells. Cancer Res 68: 6550-6558, 2008.
23. Selivanova G and Wiman KG: Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 26: 2243-2254, 2007.
24. Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH and Segall JE: Microglial stimulation of glioblas-toma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSf-1R) signaling. Mol Med 18: 519-527, 2012.
25. Curtis C, Shah SP, Chin SF, et al: The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486: 346-352, 2012.
26. Bianco R, Shin I, Ritter CA, et al: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22: 2812-2822, 2003.
27. Yi Y W, Hong W, Kang HJ, et al: Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer. J Cell Mol Med 17: 648-656, 2013.
28. Elrod HA, Lin YD, Yue P, Wang X, Lonial S, Khuri FR and Sun SY: The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther 6: 2029-2038, 2007.
29. McCubrey JA, Steelman LS, Chappell WH, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007.
30. Zwang Y, Sas-Chen A, Drier Y, et al: Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Mol Cell 42: 524-535, 2011.
31. Bouali S, Chrétien AS, Ramacci C, et al: P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab. Cancer Gene Ther 16: 498-507, 2009.
32. Kojima K, Konopleva M, Samudio IJ, et al: Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. Cancer Res 67: 3210-3219, 2007.
33. Chang GC, Yu CT, Tsai CH, et al: An epidermal growth factor inhibitor, Geftinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells. Eur J Pharmacol 600: 37-44, 2008.
34. Yu HY, Kim SO, Jin CY, Kim GY, Kim WJ, Yoo YH and Choi YH: β-lapachone-induced apoptosis of human gastric carcinoma AGS cells is caspase-dependent and regulated by the PI3K/Akt pathway. Biomol Ther 22: 184-192, 2014.
35. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ and Roth JA: Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 2: 1665-1671, 1996.
36. Lang FF, Bruner JM, Fuller GN, et al: Phase I trial of adenovirus-mediated p53 Gene Therapy for recurrent glioma: biological and clinical results. J Clin Oncol 21: 2508-2518, 2003.
37. Schuler M, Herr mann R, De Greve JL, et al: Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 19: 1750-1758, 2001.
38. Buller RE, Runnebaum IB, Karlan BY, et al: A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 9: 553-566, 2002.
39. Pan JJ, Zhang SW, Chen CB, et al: Effect of recombinant adeno-virus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol 27: 799-804, 2009.